Analyzes SLC transporters in cancer metabolism, suggesting new therapeutic strategies for treatment.
The Solute Carrier (SLC) family regulates cancer metabolism, supporting proliferation and immune evasion. Key members, such as GLUT1, LAT1, ASCT2, xCT and MCT4, drive metabolic reprogramming and are therapeutic targets. Selective inhibitors like BAY-876 show preclinical efficacy. Combining SLC inhibition with standard therapies may overcome resistance, while personalized strategies and advances in biomarkers and drug delivery are critical for clinical translation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: